In the news: Fusion Pharmaceuticals. The background image is a woman researcher working in a lab while wearing personal protective equipment (PPE).

Hamilton’s Fusion Pharmaceuticals Raises $26 Million CAD

PRECISION ONCOLOGY STARTUP FUSION PHARMACEUTICALS RAISES $26 MILLION CAD


This article originally appeared on betakit.com written by Isabelle Kirkwood.  For the original post please click this link.


Biopharmaceutical precision oncology startup Fusion Pharmaceuticals has received a commitment of up to $26 million CAD ($20 million USD) from the Canada Pension Plan Investment Board (CPPIB).

This funding comes ten months after Fusion Pharmaceuticals’ $140 million CAD Series B. The startup said the net-new capital will be used to expand the use of its platform that connects medical isotopes to targeting molecules which it says can create novel cancer treatments. It plans to expand the platform by investing in new partnerships as well as targeting molecules that could lead to new treatments.

Funds will also be put toward the company’s lead clinical candidate, FPI-1434, currently in a Phase 1 trial for treating solid tumours. FPI-1434, which Fusion Pharmaceuticals has called its “linker technology,” is intended to combine the precision targeting of an antibody with the potency of alpha-particle emitting medical isotopes. This, the company claims, helps to attack and eradicate cancer cells across multiple tumour types.

Founded in 2014 at McMaster University in Hamilton, Ont., Fusion Pharmaceuticals’ goal is to cure cancer by developing targeted alpha therapeutics, a method that employs radioactive substances that undergo radioactive decay to treat diseased tissue at close proximity.

The company views this approach as the “next generation” of radiation therapy, promoting it as a potentially safer and more effective therapy than currently available options.

The CPPIB is an investment management organization that invests the funds of the Canada Pension Plan on behalf of its 20 million Canadian contributors and beneficiaries. The organization holds investments in private equity, public equity holdings, and real estate in 52 countries. Last year, the CPPIB committed capital to Northleaf’s $300 million fund-of-funds.

“The additional capital provides opportunities for Fusion Pharmaceuticals to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients,” said Fusion Pharmaceuticals CEO John Valliant.

Share this article
Facebook
Twitter
LinkedIn
WhatsApp
Email
View All Categories

Featured iF Clients

A 6-week training & mentorship program that offers startups and growing businesses opportunities to build strategic connections, and prepare to secure investment capital.

Ready to accelerate your business growth?

Founders Fast Track is 6 week mentorship program that provides your startup with access to industry expertise, resources, networking opportunities, and skills to help you secure investment capital.

Applications are open until April 14, 2024

Synapse Life Science Pitch Competition

Get tickets for the 2024 Synapse Competition!

Innovation Factory’s Synapse Competition is Ontario’s premier life science pitch competition, dedicated to fostering innovation in the life science sector.

Why you should attend:

  • Meet the finalists at the 11th annual Synapse Competition showcase!
  • Discover emerging life science innovations
  • Network with industry leaders and a thriving life science ecosystem.

March 20, 2024 | 4:00pm – 8:00pm EDT